Clinical Trial: AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism (VTE-AI Randomized Trial)

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06939803) titled 'AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism (VTE-AI Randomized Trial)' on April 15.

Brief Summary: Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical expenses. HA-VTE is the second leading cause of long-term disability and causes significant health issues and deaths in both adults and children. About 1 in 3 people who get blood clots experience long-term complications. Reducing HA-VTE is a major challenge.

This study will test a new AI metho...